Grenoble Institute of Technology, Univ. Grenoble Alpes, 38000 Grenoble, France; CNRS, LMGP, 3 Parvis Louis Néel, 38031 Grenoble Cedex 01, France.
Tissue Engineering Laboratory, Skeletal Biology and Engineering Research Center, KU Leuven, Belgium; Prometheus, Division of Skeletal Tissue Engineering, KU Leuven, Belgium.
Biomaterials. 2018 Oct;180:143-162. doi: 10.1016/j.biomaterials.2018.07.017. Epub 2018 Jul 11.
Bone fractures are the most common traumatic injuries in humans. The repair of bone fractures is a regenerative process that recapitulates many of the biological events of embryonic skeletal development. Most of the time it leads to successful healing and the recovery of the damaged bone. Unfortunately, about 5-10% of fractures will lead to delayed healing or non-union, more so in the case of co-morbidities such as diabetes. In this article, we review the different strategies to heal bone defects using synthetic bone graft substitutes, biologically active substances and stem cells. The majority of currently available reviews focus on strategies that are still at the early stages of development and use mostly in vitro experiments with cell lines or stem cells. Here, we focus on what is already implemented in the clinics, what is currently in clinical trials, and what has been tested in animal models. Treatment approaches can be classified in three major categories: i) synthetic bone graft substitutes (BGS) whose architecture and surface can be optimized; ii) BGS combined with bioactive molecules such as growth factors, peptides or small molecules targeting bone precursor cells, bone formation and metabolism; iii) cell-based strategies with progenitor cells combined or not with active molecules that can be injected or seeded on BGS for improved delivery. We review the major types of adult stromal cells (bone marrow, adipose and periosteum derived) that have been used and compare their properties. Finally, we discuss the remaining challenges that need to be addressed to significantly improve the healing of bone defects.
骨折是人类最常见的外伤性损伤。骨折的修复是一个再生过程,它再现了胚胎骨骼发育的许多生物学事件。大多数情况下,它会导致成功愈合和受损骨骼的恢复。不幸的是,大约 5-10%的骨折会导致延迟愈合或不愈合,在合并症如糖尿病的情况下更是如此。在本文中,我们综述了使用合成骨移植物替代物、生物活性物质和干细胞来治疗骨缺损的不同策略。目前大多数可用的综述都集中在仍处于早期发展阶段的策略上,并且主要使用细胞系或干细胞进行体外实验。在这里,我们关注的是已经在临床上实施的、正在临床试验中的以及已经在动物模型中测试过的方法。治疗方法可以分为三大类:i)合成骨移植物替代物(BGS),其结构和表面可以进行优化;ii)BGS 与生物活性分子如生长因子、肽或针对骨前体细胞、骨形成和代谢的小分子结合;iii)基于细胞的策略,使用祖细胞与或不与可注射或接种于 BGS 以改善递送的活性分子结合。我们综述了已经使用过的主要类型的成人基质细胞(骨髓、脂肪和骨膜来源),并比较了它们的特性。最后,我们讨论了需要解决的剩余挑战,以显著改善骨缺损的愈合。